Cosmos Health announced the launch of a new nanotechnology research and development program aimed at enhancing the absorption, stability, and bioactivity of phytochemicals in its dietary supplement formulas. The program builds on the company’s proprietary CCX Hydrogel platform and focuses on developing plant‑based extract‑loaded phytosomes.
The initiative uses a green, solvent‑free process to create nanostructured phytosome systems that are designed to increase the bioavailability of active compounds. Management said the new platform could improve efficacy of existing products and enable the development of higher‑margin nutraceuticals.
The company’s Q2 2025 financial results showed revenue of $14.75 million, up 11.66% year‑over‑year, and gross profit of $1.16 million, a 51.60% increase. Gross margin expanded to 7.92% for FY 2024, below industry averages, prompting the shift toward higher‑margin products.
Cosmos Health’s revenue mix is currently 60% from distribution of dietary supplements and 40% from manufacturing and proprietary product sales. The new R&D program is expected to shift the mix toward the manufacturing segment, which has a higher gross margin.
The nutraceutical market is projected to grow at a CAGR of 6.2% through 2030, and consumer demand for scientifically validated, sustainable products is rising. Cosmos Health’s green, solvent‑free nanotechnology aligns with this trend and positions the company to compete with larger players.
Management highlighted that the CCX Hydrogel platform has previously improved delivery of bioactive compounds, and the new nanotechnology program will build on that success to deliver measurable efficacy improvements.
The company also continues to invest in digital assets, maintaining a $300 million digital assets facility, and is working to regain compliance with Nasdaq’s minimum bid price requirement, with an extension until November 3, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.